American pharmaceutical firm Eli Lilly and Company has announced the start of its phase 3 trial on one of its experimental COVID-19 antibody treatments.
‘Phase 3 trial will evaluate the efficacy and safety of LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19.’
Read More..
More than 40 per cent of coronavirus deaths in the US linked to long-term care facilities creates the urgent need for therapies to prevent COVID-19 in this vulnerable population, Eli Lilly and Company said in a release on Monday. Read More..
The first-of-its-kind study is expected to enrol up to 2,400 participants who live or work at facilities that have had a recently diagnosed case of COVID-19 and who are now at a high risk of exposure.
It will evaluate the efficacy and safety of LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19, testing whether a single dose of LY-CoV555 reduces the rate of SARS-CoV-2 infection through 4 weeks, as well as complications of COVID-19 through 8 weeks, said the company.
"COVID-19 has had a devastating impact on nursing home residents," said Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories, in a statement.
"We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
Advertisement
Coronavirus
Coronaviruses infect animals, humans, and birds. Human coronaviruses, such as SARS, MERS, and 2019-nCoV cause respiratory distress and even death. The S protein is the infectious agent of the virus.
Coronaviruses infect animals, humans, and birds. Human coronaviruses, such as SARS, MERS, and 2019-nCoV cause respiratory distress and even death. The S protein is the infectious agent of the virus.
Source-IANS
